In the base case of US adult hematopoietic stem cell transplant recipients, recombinant zoster vaccine was considered a ‘dominant strategy’ versus no vaccine because vaccination resulted in cost savings with quality-adjusted life-year (QALY) gains over 30 years.

Analyses of selected immunocompromised adult populations showed that vaccination with recombinant zoster vaccine is likely cost saving (renal transplant recipients) or cost effective (patients with HIV, breast cancer, and Hodgkin’s lymphoma) at a hypothetical willingness-to-pay threshold of US$100,000 per QALY gained.